Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gritstone Oncology Inc (DE:2JQ)
FRANKFURT:2JQ
RESEARCH TOOLSreports
Gritstone Oncology (2JQ) Stock Price & Analysis
1 Followers
2JQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.65 - €2.74
Previous Close€0.67
Volume0.00
Average Volume (3M)2.62K
Market Cap
€73.37M
Enterprise Value€97.27M
Total Cash (Recent Filing)$79.29M
Total Debt (Recent Filing)$104.78M
Price to Earnings (P/E)N/A
Beta0.64
Next Earnings
May 09, 2024EPS Estimate
-€0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding98,065,594
10 Day Avg. Volume595
30 Day Avg. Volume2,621
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.41
Price to Sales (P/S)4.05
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.95
Enterprise Value/Gross Profit5.95
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
€5.23Price Target Upside676.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Gritstone Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressGRTS exceeded its enrollment target in the GRANITE-1L program, indicating strong interest and potentially robust data.
Government SupportThe $430M grant from BARDA to Gritstone bio highlights the government's support for vaccines with greater immunogenicity and durability.
Technological AdvancementGritstone's EDGE neoantigen platform shows advances in capabilities, now able to predict presented neoantigens for both HLA I and II alleles with high predictive power.
Bears Say
Clinical Trial DelaysTrial initiation for GRTS' next-gen COVID vaccine has been delayed to allow for the use of full GMP-grade materials in the manufacturing process.
Financial PerformanceGritstone reported a net loss for the quarter, slightly lower than the estimated figures.
Operational ChallengesA misalignment between BARDA and FDA guidance has caused a delay in funding, leading to financial strain and operational downsizing.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
2JQ FAQ
What was Gritstone Oncology Inc’s price range in the past 12 months?
Gritstone Oncology Inc lowest stock price was €0.65 and its highest was €2.73 in the past 12 months.
What is Gritstone Oncology Inc’s market cap?
Currently, no data Available
When is Gritstone Oncology Inc’s upcoming earnings report date?
Gritstone Oncology Inc’s upcoming earnings report date is May 09, 2024 which is in 14 days.
How were Gritstone Oncology Inc’s earnings last quarter?
Gritstone Oncology Inc released its earnings results on Mar 05, 2024. The company reported -€0.244 earnings per share for the quarter, beating the consensus estimate of -€0.307 by €0.063.
Is Gritstone Oncology Inc overvalued?
According to Wall Street analysts Gritstone Oncology Inc’s price is currently Undervalued.
Does Gritstone Oncology Inc pay dividends?
Gritstone Oncology Inc does not currently pay dividends.
What is Gritstone Oncology Inc’s EPS estimate?
Gritstone Oncology Inc’s EPS estimate is -€0.3.
How many shares outstanding does Gritstone Oncology Inc have?
Currently, no data Available
What happened to Gritstone Oncology Inc’s price movement after its last earnings report?
Gritstone Oncology Inc reported an EPS of -€0.244 in its last earnings report, beating expectations of -€0.307. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gritstone Oncology Inc?
Among the largest hedge funds holding Gritstone Oncology Inc’s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc’s shares valued at 7M.
---
Gritstone Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.23 (676.89% Upside)
€5.23 (676.89% Upside)
Blogger Sentiment
Bullish
DE:2JQ Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.15%
12-Months-Change
Fundamentals
Return on Equity
-124.41%
Trailing 12-Months
Asset Growth
-26.16%
Trailing 12-Months
Company Description
Gritstone Oncology Inc
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
---
2JQ Company Deck
---
2JQ Earnings Call
Q1 2023
0:00 / 0:00
---
2JQ Stock 12 Months Forecast
Average Price Target
€5.23
▲(676.89% Upside)
Technical Analysis
Best Analysts Covering 2JQ
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-15.72%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -15.72% per trade.
---